Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr 1;33(10):1104-11.
doi: 10.1200/JCO.2014.57.1547. Epub 2014 Dec 1.

Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors

Melinda L Irwin  1 , Brenda Cartmel  2 , Cary P Gross  2 , Elizabeth Ercolano  2 , Fangyong Li  2 , Xiaopan Yao  2 , Martha Fiellin  2 , Scott Capozza  2 , Marianna Rothbard  2 , Yang Zhou  2 , Maura Harrigan  2 , Tara Sanft  2 , Kathryn Schmitz  2 , Tuhina Neogi  2 , Dawn Hershman  2 , Jennifer Ligibel  2
Affiliations
Randomized Controlled Trial

Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors

Melinda L Irwin et al. J Clin Oncol. .

Abstract

Purpose: Arthralgia occurs in up to 50% of breast cancer survivors treated with aromatase inhibitors (AIs) and is the most common reason for poor AI adherence. We conducted, in 121 breast cancer survivors receiving an AI and reporting arthralgia, a yearlong randomized trial of the impact of exercise versus usual care on arthralgia severity.

Patients and methods: Eligibility criteria included receiving an AI for at least 6 months, reporting ≥ 3 of 10 for worst joint pain on the Brief Pain Inventory (BPI), and reporting < 90 minutes per week of aerobic exercise and no strength training. Participants were randomly assigned to exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week) or usual care. The BPI, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, and Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire were completed at baseline and at 3, 6, 9, and 12 months. Intervention effects were evaluated using mixed-model repeated measures analysis, with change at 12 months as the primary end point.

Results: Over 12 months, women randomly assigned to exercise (n = 61) attended 70% (± standard deviation [SD], 28%) of resistance training sessions and increased their exercise by 159 (± SD, 136) minutes per week. Worst joint pain scores decreased by 1.6 points (29%) at 12 months among women randomly assigned to exercise versus a 0.2-point increase (3%) among those receiving usual care (n = 60; P < .001). Pain severity and interference, as well as DASH and WOMAC pain scores, also decreased significantly at 12 months in women randomly assigned to exercise, compared with increases for those receiving usual care (all P < .001).

Conclusion: Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivors.

Trial registration: ClinicalTrials.gov NCT02056067.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Flow of participants through Hormones and Physical Exercise study. AI, aromatase inhibitor; BPI, Brief Pain Index.
Fig 2.
Fig 2.
Changes in (A) worst pain, (B) severity, and (C) interference.
See this image and copyright information in PMC

References

    1. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802. - PubMed
    1. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: The Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol. 2006;17(suppl 10):x59–x62. - PubMed
    1. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: Summary of the consensus discussion. Breast Care (Basel) 2011;6:136–141. - PMC - PubMed
    1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28:3784–3796. - PMC - PubMed
    1. Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat. 2012;134:459–478. - PMC - PubMed

Publication types

Substances

Associated data